{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0006289\nAge: 68\nGender: Female\nSample ID: P-0006289-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 30.0%\n=============\nDNA Variants:\nBRAF c.1799T>A (p.V600E) - in 28.00% of 640 reads\nMAP2K1 c.364A>G (p.N122D) - in 24.00% of 989 reads\nPARP1 c.2893G>A (p.D965N) - in 29.00% of 939 reads\nPIK3C3 c.1298C>T (p.S433F) - in 6.00% of 519 reads\nSETD2 c.4492C>T (p.Q1498*) - in 22.00% of 610 reads\nSETD2 c.1968_1969dup (p.K657Ifs*3) - in 21.00% of 481 reads\nSMAD4 c.325_326del (p.L109Kfs*4) - in 34.00% of 683 reads\nTP53 c.627_649del (p.R209Sfs*5) - in 33.00% of 748 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Vemurafenib\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": \"BRAF V600E mutation\",\n    \"FDA-approval status\": \"FDA-approved for BRAF V600E-mutant metastatic non-small cell lung cancer\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209944s000lbl.pdf\"\n  }\n}"
}